Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06530966 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of ICP-332 in Healthy Subjects
A Phase 1 study of Healthy Subjects, sponsored by InnoCare Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06530966: Recruiting Phase 1 study of Healthy Subjects, sponsored by InnoCare Pharma.
NCT06530966 is a Phase 1 study of Healthy Subjects that is actively recruiting participants, run by InnoCare Pharma. The registered enrollment target is 24 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06530966, a Phase 1 study of Healthy Subjects, is actively recruiting participants, sponsored by InnoCare Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
A multiple ascending dose phase I study of ICP-332 in healthy subjects
Conditions Studied
Interventions
- DRUG ICP-332 Tablets
- DRUG ICP-332 Placebo Tablets
Study Locations (1)
Maryland
- Pharmaron CPC Inc. - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-07-23 |
| Est. Completion | 2024-12-25 |
| Phase | Phase 1 |
What NCT06530966 shows while recruiting
NCT06530966 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 2 interventions - of which ICP-332 Tablets is the first listed.
NCT06530966 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06530966 about?
NCT06530966 is a clinical study titled "Phase I Study of ICP-332 in Healthy Subjects". A multiple ascending dose phase I study of ICP-332 in healthy subjects
What is the current status of trial NCT06530966?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-07-23. Estimated completion is 2024-12-25.
What conditions does trial NCT06530966 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT06530966?
The interventions under investigation include: ICP-332 Tablets (DRUG), ICP-332 Placebo Tablets (DRUG).
Who is sponsoring clinical trial NCT06530966?
This trial is sponsored by InnoCare Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06530966 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06530966's enrollment target sits among peer trials
24 46th of 69 higher than 18 of 69 other Healthy Subjects trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Subjects trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
-
A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI